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ABSTRACT
Tumor-initiating cells constitute a population within a tumor mass that shares 
properties with normal stem cells and is considered responsible for therapy failure 
in many cancers. We have previously demonstrated that knockdown of the nuclear 
envelope component Lamin A/C in human neuroblastoma cells inhibits retinoic acid-
mediated differentiation and results in a more aggressive phenotype. In addition, 
Lamin A/C is often lost in advanced tumors and changes in the nuclear envelope 
composition occur during tumor progression. Based on our previous data and 
considering that Lamin A/C is expressed in differentiated tissues, we hypothesize 
that the lack of Lamin A/C could predispose cells toward a stem-like phenotype, thus 
influencing the development of tumor-initiating cells in neuroblastoma. This paper 
demonstrates that knockdown of Lamin A/C triggers the development of a tumor-
initiating cell population with self-renewing features in human neuroblastoma cells. 
We also demonstrates that the development of TICs is due to an increased expression 
of MYCN gene and that in neuroblastoma exists an inverse relationship between LMNA 
and MYCN expression.
INTRODUCTION
Neuroblastoma (NB) is the most common 
childhood (15% of deaths in children) extracranial 
tumor of the autonomic nervous system that originates 
from neural crest-derived sympathoadrenal progenitors. 
The clinical behavior of NB is correlated with specific 
genomic abnormalities and high level amplification of 
the MYCN oncogene [1]. Treatment for patients with 
advanced disease is aggressive multimodal therapy 
(e.g. intensive chemotherapy, radiation, surgery, 
hematopoietic stem cell rescue and immunotherapy) 
even though the survival of these patients remains at 
40–50%.
A reservoir of tumor cells (within a tumor) that 
has similar properties to normal stem cells might 
be responsible for therapy failure during long-term 
remission. This subpopulation of cells has been termed 
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cancer stem cells (CSCs) or tumor-initiating cells 
(TICs). Although hematopoiesis is the most thoroughly 
studied stem cell system, local resident stem cells could 
maintain several other organs and many solid tumors, 
including NB, may contain a population of TICs [2, 3]. 
However, we know little about the phenotype of NB-
TICs. To individuate TICs within a tumor, researchers 
normally focus on the study of functional stem cell-like 
characteristics such as self-renewal, tumorigenicity and 
drug resistance [4].
In a previous paper, we have shown that knockdown 
of Lamin A/C expression in NB cells inhibits cell 
differentiation and gives rise to a more aggressive and 
drug-resistant tumor phenotype [5]. Lamins, which are 
type V intermediate filaments, are the major components 
of the nuclear lamina. They are divided into A and B 
types based on similarities in their primary sequences 
and biological properties; A- and B-type lamins are 
expressed in differentiated tissues and ubiquitously, 
respectively [6, 7]. Additionally, the expression of A-type 
lamins is often reduced or absent in cells that are highly 
proliferative, including various malignancies [8, 9]. 
Based on our previous data and considering the different 
expression of Lamin A/C during development, we 
hypothesize that the lack of Lamin A/C could predispose 
cells toward a more immature phenotype. The aim of 
the present paper is to investigate whether Lamin A/C 
expression levels could influence the presence of TICs 
in NB.
Moreover, we seek to study the mechanism by 
which Lamin A/C could control tumor aggressiveness 
in NB. Changes in the composition of the nuclear 
membrane occur during the progression of several types 
of cancers [10, 11]. Good functionality of the nuclear 
membrane could play a crucial role in biological 
functions such as microRNA (miRNA) processing. 
miRNA expression is a complex process that requires an 
initial step of maturation in the nucleus, an intermediate 
phase of nuclear export, and a final processing of the 
pre-miRNA into the mature miRNA in the cytoplasm 
[12]. miRNAs are critical in controlling the self-renewal 
and differentiation of embryonic stem cells [13] and 
aberrant expression and/or functions of miRNAs are 
associated with tumorigenesis and the metastasis in 
many forms of cancer, including NB [14, 15]. The 
mechanisms leading to miRNA dysregulation in NB are 
still not fully understood. Several miRNAs, including 
the miR-17–92 cluster, are induced by the NB-specific 
transcription factor MYCN [16–18]. On the other hand, 
certain miRNAs, such as miR-101, influence MYCN 
transcription [19].
The data herein demonstrate that knockdown of 
Lamin A/C triggers the development of a TIC population 
with self-renewal features in human NB cells.
RESULTS
Abundance of LMNA in NB tumors is inversely 
correlated with that of MYCN gene
We analyzed the expression levels of the LMNA 
and MYCN genes in 23 NB biopsies obtained from the 
Department of Pediatrics and Infantile Neuropsychiatry 
of Sapienza University. The tumors were classified 
according to the International Neuroblastoma Pathology 
Classification (INPC) and staged as stages 1 to 4. Nine 
of 23 cases showed amplification of MYCN DNA. 
The expression levels of the two genes significantly 
inversely correlated (p = 0.01), independently of the 
DNA amplification of MYCN, in 21 out of the 23 
cases analyzed; i.e., as LMNA increased, MYCN gene 
expression decreased (Fig. 1).
We decided to study this inverse relationship 
between LMNA and MYCN gene in an in vitro 
experimental model of NB. We choose the SH-SY5Y 
and LAN-5 NB cell lines, with N-type morphology. The 
SH-SY5Y cells express Lamin A/C at high levels and have 
single copy of MYCN gene [20]; while LAN-5 cells show 
an amplification of the MYCN gene and do not express 
Lamin A/C [20]. In particular, since Lamin A/C has been 
demonstrated to play an epigenetic role in regulating gene 
expression and miRNAs can be targeted by MYCN, we 
hypothesized a possible reciprocal regulation between the 
two genes mediated by miRNAs.
We performed a miRNA expression profiling 
of LAN5 and SH-SY5Y cells using TaqMan Human 
MicroRNA Arrays. A total of 768 miRNAs, present in 
the array, were analyzed in each cell line. The distribution 
of the expressed miRNAs is shown in a Venn diagram 
where a total of 417 (66 specific and 351 common) and of 
395 (44 specific and 351 common) miRNAs were found 
expressed in LAN-5 and SH-SY5Y cells, respectively 
(Fig. 2A). We found 359 and 337 miRNAs not expressed 
in SH-SY5Y and LAN-5 cells, respectively (293 not 
expressed at all in both cell lines). We identified a set 
of 202 out of the 351 common miRNAs differentially 
expressed at least 2-fold change between the two cell 
lines (99 in the LAN-5 and 103 in the SH-SY5Y cells); 
whereas 149 miRNAs were filtered out by the threshold 
applied. A scatter plot analysis shows the correlation 
between miRNA expression values (Ct) in LAN-5 and SH-
SY5Y cell lines (Fig. 2B). Grey dots distributed along the 
bisector line represent miRNAs similarly expressed in the 
two lines (n = 149). While, red or green dots correspond 
to miRNAs with high expression in the LAN-5 (n = 165) 
and SH-SY5Y (n = 147), respectively.
Considering the specifically and the differentially 
expressed miRNAs we performed a functional analysis 
using the DIANA-mirPath 2.0 tool, and in particular the 
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software TarBase which uniquely clusters those miRNAs 
whose targets are experimentally validated [21]. We 
filtered the clusters obtained based on their significance 
(FDR corrected p < 0.05). As to be expected, target genes 
resulted grouped into functional categories associated with 
cancer phenotype. The most modulated miRNAs in both 
cell lines belong to pathways involved in the regulation 
of cell proliferation, apoptosis, and response to treatment: 
“p53 signaling pathway”, “cell cycle”, “pathways in 
cancer”, “PI3K-Akt signaling pathway”, “transcriptional 
misregulation in cancer”. These pathways are consistent 
with the inherent phenotypic characteristics of the two 
cell lines and correlate to their different capacity to 
proliferate, to undergo apoptosis, to migrate and invade 
(Supplementary Table 1). Since a single miRNA can 
inhibit several target mRNAs and multiple miRNAs 
can target a single mRNA in a combinatorial fashion, 
to identify more accurately the differences between 
Figure 1: The expression of LMNA and MYCN are inversely correlated in NB human biopsies. qRT-PCR analysis of 
the LMNA (white) and MYCN (black) genes in 23 NB human biopsies. Data (means + SD [n = 3]) are reported as the deltaCt values 
normalized against the endogenous control. The deltaCt values are inversely correlated with the amount of the gene present in the sample. 
Statistical significance: p ≤ 0.01.
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the miRNome profiles of these two NB cell lines, we 
intersected the target genes derived from the two cell lines 
in order to identify the identical genes which were then 
removed from the analysis. In Table 1 are reported target 
genes, and relative miRNAs, identified only in SH-SY5Y 
or LAN-5 cells after removing the identical genes. The 
gene ontology performed using the DAVID tool on this 
subset of target genes evidenced that the most relevant 
enriched functional categories identified in SH-SY5Y 
cells were associated with cell migration, locomotion and 
cell proliferation (Fig. 2C and Table 2). This indicates 
that SH-SY5Y cells, which express LMNA gene, have 
a reduced ability to migrate, to proliferate and hence to 
be aggressive. Whereas, the LAN-5 cells, which instead 
express MYCN gene, showed an enrichment in functional 
categories associated with regulation of differentiation and 
cell proliferation suggesting that these cells are less prone 
to differentiate and might show a stem-like phenotype 
with respect to SH-SY5Y cells (Fig. 2C and Table 2). On 
the basis of these results, we hypothesize that the mutual 
expression of MYCN and LMNA genes could address 
NB cells to a stem-like or a differentiating phenotype, 
respectively.
To validate the results obtained in cell cultures 
we analyzed the expression of some selected miRNAs 
in tumor tissue RNA specimens previously studied 
for LMNA and MYCN expression. Among the most 
differentially expressed miRNAs between SH-SY5Y and 
LAN-5 cell lines, we chose miR-101, miR-34a, miR-424, 
miR-21, miR-504 and miR-92a which clearly represent 
the phenotypic differences between the two cell lines 
as concerns tumorigenicity and NB tumor progression, 
regulation of cell cycle, differentiation and targeting of 
MYCN. The distribution of the deltaCt values of all the 
miRNAs studied in 15 tumor tissue specimens resulted 
very heterogeneous as evidenced in the box plot shown 
(Fig. 3A). To obtain a more accurate analysis we divided 
the samples in two groups with high (≤ -1.00) and low 
(> -1.00) LMNA expression (threshold = LMNA deltaCt 
median value), including only those specimens whose 
difference between LMNA and MYCN expression was 
at least 4-fold (12 out of 15 tumor tissue specimens). 
Consistent with the changes observed in the two cell lines 
we found an increased expression of miR-101, miR-34a, 
miR-424, miR-21, and a decreased expression of miR-504 
and miR-92a in the NB patient group with high LMNA 
expression compared with the specimen group with low 
LMNA expression (Fig. 3B).
LMNA gene knock-down induces a stem-like 
phenotype in SH-SY5Y cells
We used as experimental model the SH-SY5Y 
cells in which we previously inhibited differentiation by 
LMNA knock-down (LMNA-KD) [5]. First, we analyzed 
the expression of some stemness-related markers such as 
NANOG, SOX2, POU5f, PROM-1, CD34 and ABCG2, 
by qPCR (Fig. 4A). All of these genes were overexpressed 
in LMNA-KD cells, indicating that lack of the LMNA 
gene could be associated with a more immature cell 
phenotype. The activity of ABCG2, which is a member of 
the ATP-binding cassette (ABC) membrane transporters, 
and present in many types of stem cells, was also verified 
evaluating by FACS analysis the exclusion of the 
fluorescent supravital dye Hoechst 33342 out of the cells. 
The cells able to pump outside the dye are concentrated in 
a tailing population exhibiting dim fluorescence relative 
to the majority of cells with bright fluorescence and 
they represent the so called “side population”, known to 
correlate with a stem-like phenotype. Indeed, LMNA-KD 
cells show the presence of a side population identified by 
a Hoechst 33342 low-staining fraction (approximately 5%; 
Fig. 4B). As control to confirm dye efflux and the probable 
presence of stem-like cells we inhibited the ABCG2 pump 
by verapamil. Consistently, verapamil treatment led to 
depletion of this side population in LMNA-KD cells. By 
contrast, control cells presented the same cytofluorimetric 
profile in both the presence and absence of verapamil.
We then investigated the ability to form spheres by 
LMNA-KD cells in the appropriate culture conditions. 
As a positive control, we used human NB LAN-5 cells, 
known to form spheres [3]. Similarly to LAN-5 cells, 
LMNA-KD cells formed secondary spheres in serum-free 
medium (Fig. 4C). Noteworthy, the mean diameter of the 
spheres measured in LMNA-KD cells was superimposable 
to that of the LAN-5 positive control cells (p = 0.18; 
Fig. 4D). By contrast, control cells did not show any 
significant capacity to form secondary spheres. We carried 
out immunofluorescence experiments on the spheres to 
detect the expression of known stemness markers, such as 
CD133, SSEA4 and SOX2. LMNA-KD secondary spheres 
were positive for all the markers considered (Fig. 4E and 
Supplementary Fig. 1).
LMNA-KD sphere-derived adherent cells 
maintain stemness characteristics and acquire a 
more aggressive phenotype
Spheres formed from LMNA-KD cells were 
cultured in adherent conditions for several passages. 
Sphere-derived adherent cells grew as discrete groups 
of differently sized cells whereas the LMNA-KD cell 
monolayer showed a dispersed pattern, with growing cells 
being mainly isolated (Supplementary Fig. 2). We verified 
the expression of MYCN mRNA levels which significantly 
increased in LMNA-KD cells and in sphere-derived 
adherent cells (approximately 2-fold) compared with CTR 
cells thus confirming our hypothesis (Fig. 5A, left panel). 
The increased MYCN expression was associated with 
the down-regulation of the NDRG1 and NDRG2 genes 
in LMNA-KD cells and in sphere-derived adherent cells 
(Fig. 5A, right panel). An increase in the N-Myc protein 
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Figure 2: Functional analysis of miRNA target genes in LAN-5 and SH-SY5Y cell lines. A. Venn diagram of expressed 
miRNAs in SH-SY5Y and LAN-5 cells. The number in parenthesis represents the total miRNAs expressed in each line. B. Scatter plot of 
the miRNA Ct values normalized against endogenous controls in SH-SY5Y and LAN-5 cells. Grey dots represent unchanged miRNAs 
between the two cell lines; green dots are the SH-SY5Y miRNAs; red dots represent LAN-5 miRNAs. C. Gene ontology by DAVID. In 
the histogram are reported the number of target genes belonging to the indicated functional categories. Red bar, LAN-5 cells; green bar, 
SH-SY5Y cells. Statistical significance: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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accompanied the increase in MYCN gene expression in 
LMNA-KD cells and sphere-derived adherent cells, as 
evaluated by FACS analysis (approximately 40 and 65%, 
respectively; Fig. 5B).
We characterized the LMNA–KD sphere-derived 
adherent cells to evaluate the mRNA expression levels 
of self-renewal genes compared to those in the control 
cell line. The stemness marker genes maintained their 
expression or were further up-regulated in LMNA-KD 
sphere-derived adherent cells (Fig. 5C). In particular, we 
observed a strong up-regulation of the stemness network 
of the transcription factor genes NANOG, POU5f and 
SOX2 and of the drug resistance-related gene ABCG2. In 
addition, sphere-derived adherent cells maintained their 
self-renewal ability, as they were still able to form cell 
spheres in non-adherent culture conditions.
We used murine embryonic stem cells (mES) to 
study the expression of Lamin A/C protein in a pluripotent 
stem cell model. mES, cultured in stemness conditions, 
homogeneously showed the presence of OCT4 (data 
not shown). When Leukemia inhibitory factor (LIF, an 
interleukin 6 class cytokine that affects cell growth by 
Table 2: Gene Ontology analysis on the target genes specifically expressed only in SH-SY5Y or 
LAN-5.
SH-SY5Y
GOTERM P value Count Target Genes
GO:0051726~regulation of cell 
cycle 4.84E-16 25
STAT5A SFN CCNG2 CDC37 TGFB2
CASP3 CDKN2A CDKN2C INSR MYC
BMP2 TP53 SKP2 CDC23 BIRC5
RB1 CDC25C ATM CDKN1B HDAC1
CCND3 CCND2 JUN MDM2 GADD45A
GO:0030335~positive regulation 
of cell migration 1.21E-11 13
IL6 PLD1 PDGFB MAP2K1 PDGFA
MMP9 IRS1 TGFB2 IGF1R MAPK1
THBS1 INSR PIK3R1
GO:0007049~cell cycle 5.21E-11 29
E2F3 CDC14A ANAPC13 SESN1 CCNG2
TGFB2 CCNE1 CDKN2A CDKN2C THBS1
MYC, MAP2K1 TP53 SKP2 CDC23
BIRC5 RB1, CDC25C APPL1 ATM
TP73 MAPK1 CDKN1B EP300 CCND3
CCND2 MDM2 MDM4 GADD45A
GO:0001952~regulation of cell-
matrix adhesion 0.002 4 CDKN2A PIK3CB THBS1 PIK3R1
GO:0007626~locomotory behavior 0.003 9
MAPK1 PLD1 IL6 MAP2K1 PDGFB
PDGFA PIK3CB RALA TGFB2
LAN-5
GOTERM P value Count Genes
GO:0051094~positive regulation 
of developmental process 9.707E-05 7
BAX RHOA SMAD3 NFKB1 SMAD2
THBS1 FGF2
GO:0001952~regulation of cell-
matrix adhesion 0.002 3 PRKCZ SMAD3 THBS1
GO:0008285~negative regulation 
of cell proliferation 0.003 6
BAX NKX3-1 SMAD3 SMAD2 THBS1
FGF2
GO:0045597~positive regulation 
of cell differentiation 0.004 5 RHOA SMAD3 NFKB1 SMAD2 FGF2
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Figure 3: miRNA validation in NB human biopsies. A. Boxplot diagrams of deltaCt values of the indicated miRNAs. Each box 
represents the distribution of the deltaCt measured for a single miRNA in 15 tumor tissue specimens. Bottoms and tops of the boxes define 
the 25th and 75th percentile, the band inside the box defines the median, and the ends of the whiskers define the lowest and the highest 
value of all data. B. Data are expressed as percentage variation (+SD) of the indicated miRNAs in the NB patient group with high LMNA 
expression compared with the specimen group with low LMNA expression, defining high and low LMNA expression on the LMNA deltaCt 
median values (threshold = -1.00) (p = 0.008).
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Figure 4: SH-SY5Y LMNA-KD cells acquire stemness characteristics. A. qRT-PCR analysis of the indicated genes in control 
(CTR; white) and LMNA-KD (black) cells. The data are reported as the level of mRNA relative to the number of control cells and are the 
means+SD (n = 5). Statistical significance: *p ≤ 0.05, **p ≤ 0.01. B. Flow cytometric analysis of side population after staining with Hoechst 
33342 in the absence or presence of verapamil to inhibit the functionality of the membrane ABCG2 efflux pump. C. Tumor sphere assay of 
LMNA-KD cells compared to control and LAN-5 cells; phase contrast micrographs of the secondary spheres, magnification 200X. D. Mean 
diameter (+SD) of the secondary spheres formed in LMNA-KD cells and compared with those obtained in LAN-5 cells (p = 0.18). The 
SH-SY5Y cells did not produce any measurable spheres but only aggregates. E. Representative confocal images of the secondary tumor 
spheres. CD133 immunostaining (red) and nuclear staining (blue). Scale bar: 50 μm.
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Figure 5: LMNA–KD sphere-derived adherent cells possess self-renewal and tumor progression characteristics.  
A. RT-qPCR analysis of MYCN mRNA levels (right panel) and of NDRG1 and NDRG2 mRNA levels (left panel) in CTR cells (white), 
LMNA-KD cells (grey) and LMNA–KD sphere-derived adherent cells (black). The data are reported as the level of mRNA relative to CTR 
cells and are the means+SD (n = 5). Statistical significance: *p ≤ 0.05 **p ≤ 0.01, ***p ≤ 0.001. B. FACS analysis of N-Myc expression in 
control and LMNA-KD cells. LAN-5 cells were used as a positive control. The number reported in each histogram represents the percent 
positivity. C. RT-qPCR analysis of the indicated genes in CTR cells (white), LMNA-KD cells (grey) and the sphere-derived adherent cell 
line (black). The data are reported as the level of mRNA relative to LMNA-KD cells and are the means+SD (n = 5). Statistical significance: 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. D. Representative immunofluorescence for Oct4 (red fluorescence) on mES culture, 4 days after 
exposure to growth medium lacking LIF interleukin, attesting the pluripotency of the cells. The absence of a signal for Oct4 and the 
presence of Lamin A/C (green fluorescence) demonstrate the luck of pluripotency and the beginning of the differentiation process. Nuclei 
were stained with DAPI (blue fluorescence). Scale bars: 20 μm. E. Relative expression of tumor aggressiveness-related genes in CTR cells 
(white), LMNA-KD cells (grey) and the sphere-derived adherent cell line (black). The data are reported as the level of mRNA relative to 
LMNA-KD cells and are the means+SD (n = 5). Statistical significance: **p ≤ 0.01, ***p ≤ 0.001.
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inhibiting differentiation) was removed from the culture 
medium, allowing a generic differentiation, we detected 
the presence of Lamin A/C in those cells that did not 
express OCT4 anymore, suggesting that Lamin A/C could 
be an exclusive characteristic of the cells that begin the 
differentiation process (Fig. 5D).
Sphere-derived adherent cells appeared to acquire 
a more aggressive phenotype than LMNA-KD cells 
(Fig. 5E). The ENPP2 metastasis-associated gene 
showed a 4-fold increase with respect to LMNA-KD 
cells. In addition, the EDN1 and CD44 genes, known 
to be involved in cell adhesion functions, significantly 
decreased in the sphere-derived adherent cell line.
Mainly, these data strongly suggest that LMNA–
KD sphere-derived adherent cells possess self-renewal 
and tumor progression characteristics that are peculiar of 
a putative population of tumor-initiating cells (TIC-like 
cells).
The LMNA-KD sphere-derived adherent cell 
line is able to initiate tumors in vivo
We performed a limiting dilution assay in LMNA-
KD sphere-derived adherent cells (namely TIC-like cells 
in this paper) to determine the minimum cell dilution 
capable of forming colonies in vitro. While TIC-like cells 
maintained colony forming ability at very low dilution 
(down to 16 cells), LMNA-KD cells did not form colonies 
at such dilution (Fig. 6A).
On this basis, we compared the in vivo growth of 
the two cell lines using an in vivo limiting dilution assay. 
Immunosuppressed mice were injected subcutaneously 
with different number of LMNA-KD and TIC-like cells 
(from 5 × 104 to 1 × 107). No differences in terms of tumor 
appearance and tumor growth were evident injecting 
from 2.5 × 105 to 1 × 107 TIC-like and LMNA-KD cells 
(data not shown). While, at lower number, TIC-like 
cells exhibited a higher growth rate than LMNA-KD 
cells (Fig. 6B); this was evident when mice were injected 
with 105 cells (left panel), but a more marked difference 
between TIC-like and LMNA-KD cells was found in 
terms of tumor mass when 5 × 104 cells were injected 
per mouse (right panel). In fact, a significant increase 
in the weight of the TIC-like-derived tumors compared 
to the LMNA-KD-derived tumors (an almost doubling) 
was observed as the maximum effect (on day 14 after 
tumor cell injection) ( p = 0.003). A significant difference 
between the two tumor growth rate was maintained also at 
day 21 and 28 after tumor cell injection ( p = 0.01).
The histopathological pattern of these tumors, 
analyzed on day 27 of tumor growth, showed small cells 
with round to oval shapes, deeply stained nuclei and 
poorly defined cytoplasmic outlines. Unlike LMNA-
KD-derived tumors, TIC-derived tumors were mainly 
microscopically characterized by a nodular pattern of 
growth. Small aggregates with mostly hyperchromatic 
nuclei were defined by the presence of fibrous septa. We 
also observed hypercellularity and overlapping nuclei 
occasionally exhibiting small nucleoli in TIC-derived 
tumors. These findings further demonstrate the more 
malignant phenotype of TIC tumors (Fig. 6C).
MYCN expression is increased by miR-101 
inhibitor in SH-SY5Y NB cells
From a more accurate analysis of the table 1 we 
found that MYCN gene appeared as one of the miRNA 
target in the SH-SY5Y cells, whereas LMNA did not 
emerge as a miRNA-regulated gene in the LAN-5 cells, 
thus indicating that the absence of MYCN expression 
in SH-SY5Y cell line might be the results of miRNA 
regulation. Since miR-101 is a specific miRNA known to 
target also MYCN gene [19, 22], we inhibited miR-101 in 
SH-SY5Y control cells to modulate MYCN expression. As 
control, we overexpressed miR-101 in LMNA-KD cells in 
order to verify the effect on MYCN gene expression. As 
expected, the analysis of the intrinsic expression of miR-
101 in both cell lines, revealed miR-101 less expressed in 
LMNA-KD cells by 50% compared to SH-SY5Y control 
cells (Fig. 7A).
Transfection of SH-SY5Y control cells with the 
miR-101 inhibitor decreased the expression levels of 
miR-101 by approximately 50% (Fig. 7B, left panel). 
Transfection of LMNA-KD cells with the miR-101 
mimic resulted in approximately 90-fold increased 
expression of miR-101 (Fig. 7B, right panel). The 
analysis of the MYCN transcripts resulted significantly 
increased or decreased after transduction of miR-101 
inhibitor or mimic, respectively (Fig. 7C). We then 
analyzed the mRNA levels of genes involved in some 
of the MYCN-regulated pathways such as stemness 
and aggressiveness. The expression of the same genes 
up-regulated in SH-SY5Y control cells after the 
inhibition of miR-101, decreased in LMNA-KD cells 
after the overexpression of miR-101. Consistently, after 
inhibiting miR-101, SH-SY5Y control cells showed 
down-regulation of the tumor suppressor EDN1 and 
CD44 genes, and increased expression of the tumor 
progression ENPP2 gene with respect to LMNA-KD 
cells transfected with the miR-101 mimic (Fig. 7C). 
We also verified the effect of the N-Myc transcription 
factor on the LMNA gene expression by analyzing the 
expression of LMNA gene in SH-SY5Y in which we 
overexpressed MYCN either by inhibiting miR-101 or 
by ectopically transducing a MYCN construct. In both 
cases we did not observe any increase in the expression 
of the LMNA gene and of the Lamin A/C protein (data 
not shown).
DISCUSSION
This paper demonstrates that the down regulation 
of Lamin A/C expression in the SH-SY5Y NB cells 
allows the development of a tumor-initiating cell (TIC) 
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Figure 6: The LMNA-KD sphere-derived adherent cell line is able to initiate tumor growth in vivo. A. In vitro plating 
efficiency (PE %) in LMNA-KD (white) and sphere-derived adherent (black) cells at different cell dilutions. B. LMNA-KD (•) or sphere-
derived adherent (○) cells were injected subcutaneously into the flanks of immunosuppressed mice at 105 (left panel) or 5 × 104 (right panel) 
cells/mouse in 200 μl of Matrigel. When a tumor mass was evident, the tumor sizes were measured, and the tumor weight was calculated 
using the following formula: a × b2/2, where a and b are the long and short diameters of the tumor, respectively. The mean ± SD tumor 
weights are reported (p = 0.003, at day 14 and p = 0.01 at day 21 and 28 after tumor cell injection). C. Histopathological examination of 
tumor biopsies from LMNA-KD cells and TICs after 27 days of tumor growth. Images shown are at 20X (left panels) and 40X (right panels) 
magnification.
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Figure 7: Modulation of hsa-miR-101 modifies the expression of MYCN gene and in turn of stemness and  
cancer-related genes. A. TaqMan MicroRNA Assay with hsa-miR-101 in CTR cells (white) and LMNA-KD cells (black). The data are 
reported as the level of mature miRNA and mRNA relative to CTR cells and are the means+SD (n = 5). Statistical significance: *p ≤ 0.05, 
**p ≤ 0.01. B. TaqMan MicroRNA Assay, with the hsa-miR-101 levels in CTR cells transfected with the inhibitor (white, left panel) or in 
LMNA-KD cells transfected with the mimic (black, right panel). The data are reported as the level of mature miRNA compared to each 
relative negative control and are the means+SD (n = 5). Statistical significance: ***p ≤ 0.001. C. qRT-PCR analysis of the indicated genes in  
hsa-miR-101 mimic-transfected LMNA-KD cells (black) and hsa-miR-101 inhibitor-transfected CTR cells (white). The data are reported as 
the level of mRNA compared to each relative negative control and are the means+SD (n = 5). Statistical significance: *p ≤ 0.05, **p ≤ 0.01,  
***p ≤ 0.001.
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population with self-renewal features and the ability to 
initiate tumors in vivo.
TICs have been identified in many tumor types as a 
small tumorigenic population of cells that are responsible 
for sustaining tumor growth and metastatic spread, thus 
representing the cause of cancer recurrence [23–25]. Their 
presence has been demonstrated in the bone marrow of 
patients with relapsed NB [2], and they have many stem 
cell characteristics, such as sphere-forming ability and 
self-renewal. However, sphere-forming ability is not a 
general characteristic of NB tumor-derived cell lines, 
as reported by Mahller and colleagues [3], who studied 
the capacity to give rise to spheres in eight NB cell lines, 
including SH-SY5Y. In accordance with these authors, 
we also found that NB SH-SY5Y cells were not able to 
form spheres. However, when we silenced the LMNA 
gene in these cells, they gave rise to spheres in serum-
free culture conditions that were optimized for neural 
stem cell growth. The capacity to form spheres clearly 
demonstrates that this selected population possesses the 
self-renewal characteristics of a stem cell phenotype. 
Pluripotency is a unique state in which cells can self-renew 
indefinitely while maintaining the ability to differentiate. 
The mechanism that controls the transcription of core 
pluripotency factors has been extensively studied [26, 27]. 
In normal embryonic stem cells, the gene regulatory 
networks of the core transcription factors Oct4, Nanog 
and Sox2 are involved in pluripotency maintenance 
[27]. Consistently, we found that the three main genes 
belonging to the stem cell regulatory network (POU5f, 
which encodes Oct4, NANOG and SOX2) were all 
significantly overexpressed in LMNA-KD-derived tumor 
spheres and even more so when the sphere cell population 
was cultured as adherent cells.
In addition, the fact that these spheres are highly 
positive for the CD133, SOX2 and SSEA4 markers further 
supports the stem-like phenotype of LMNA-KD cells.
We also found in LMNA-KD-derived tumor 
spheres a marked increase in the expression of the ABC 
membrane transporter gene ABCG2. Increased expression 
of this gene is considered a major characteristic of 
the cancer stem cell population that is associated with 
different tumor types [28]. The increased expression of 
this drug resistance-related gene often correlates with the 
presence of a side population [29]. Indeed, we found the 
unambiguous presence of a side population completely 
abolished by the exposure to verapamil, a known inhibitor 
of the membrane drug efflux-pump, in LMNA-KD cells.
To further corroborate that this cell population with 
self-renewal characteristics was a TIC population, we 
studied the capacity of these cells to give rise to tumors. 
The analysis of tumor growth in vivo clearly demonstrated 
that the putative TICs were more markedly aggressive, 
as evidenced by their significant higher growth rate at 
low cell concentrations than the LMNA-KD whole cell 
population and by the more malignant phenotype of the 
tumor tissues. It is likely that the enhanced tumorigenicity 
of TICs may depend on their maintenance in supportive 
micro-environmental “niches”. In normal tissues a “niche” 
consists of a microenvironment formed by cellular and 
non-cellular components which together are able of 
housing and maintaining stem cell homeostasis. On the 
other hand, there is evidence that the normal cells that 
surround and infiltrate tumors secrete factors that promote 
the growth and progression of cancer. Vermeulen et al. 
[30] reported that the microenvironment was imperative 
for regulating functional activity associated to colon 
TICs. Similarly, Calabrese et al. [31] demonstrated that 
brain vascular niche is responsible for promoting self-
renewal and accelerating tumor growth from brain TICs. 
As reported by others in different tumor types including 
neuroblastoma [2, 32] we also used Matrigel in our 
in vivo studies in order to provide to TICs a complete 
microenvironment and biological substrates to promote 
TIC xenograft tumor formation.
The aggressiveness of the TIC population was also 
evidenced by increase of ENPP2 and decrease of EDN1 
and CD44 gene expression. We can therefore conclude 
that the LMNA-KD sphere-derived cells represent a TIC 
population.
The inverse relationship between LMNA and the 
NB marker MYCN found in the TICs indicate that these 
two genes could mutually regulate differentiation and 
stemness in NB. Indeed, TICs which express more MYCN 
than SH-SY5Y control cells and are silenced for LMNA 
gene, also show a significant increase of the NANOG, 
POU5f and SOX2 gene expression. This is supported by 
the data obtained from biopsies of human NB. Indeed, we 
found, for the first time in this paper, a defined inverse 
relationship between LMNA and MYCN gene expression 
in 23 human NB biopsies.
On the other hand, the miRNome analysis in two NB 
cellular model expressing LMNA or MYCN alternatively, 
evidenced changes of members of miRNA signatures which 
control cell proliferation and differentiation. In fact, in the 
SH-SY5Y LMNA expressing cells DAVID pathway analysis 
revealed that the miRNA target genes belonged mainly to 
pathways related to cell cycle regulation indicating that the 
expression of Lamin A/C is associated with a more mature 
phenotype. This confirm data of a previous paper from our 
laboratory where we demonstrated that LMNA knock-down 
inhibit differentiation processes. By the contrary, in the 
LAN-5 MYCN expressing cells the miRNA target genes 
identified belonged to pathways related to the inhibition of 
the developmental processes. In particular, some of these 
genes (SMAD2/3, FGF2) appear to be involved in stem cell 
differentiation processes [33, 34]. The very different number 
of miRNAs identified in each cluster comparing the two 
cell lines support our hypothesis. It is likely that miRNAs 
and their target genes in LAN-5 cells tend to display a low 
number of clusters as a consequence of reduced number 
of pathways to be regulated to maintain their stem-like 
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phenotype. By contrast, SH-SY5Y cells need to control a 
higher number of pathways than LAN-5 cells, due to their 
more mature phenotype. On the other hand, it is important 
to highlight that the analysis has been performed considering 
uniquely validated target. The validation in NB human 
specimens of some of the relevant miRNAs differentially 
expressed in the two NB cell lines confirms in the tumor 
biopsies the expression profiles obtained in the two cell 
lines. This suggests that this group of miRNAs could be 
the basis for a further identification of a miRNA signature 
representative of tumor progression in relation to LMNA 
expression.
The MYCN crucial role in the control of tumor 
initiating cell development is further demonstrated by 
data obtained modulating MYCN expression through 
miR-mediated regulation. The choice to modulate MYCN 
by miR-101 mediated regulation is based on the analysis 
of the miRNA array performed in SH-SY5Y and LAN-5 
cells (see supplementary table 1). We evidenced hsa-miR-
101–3p and hsa-miR-34a-5p as specific miRNAs targeting 
MYCN gene [19]. To confirm that these miRNAs were 
expressed at higher levels in SH-SY5Y than in LAN-5 cells 
we performed a qRT-PCR which confirmed the array result 
(data not shown). In addition, only miR-101 expression 
was decreased in LMNA-KD compared to control cells; 
while the expression of miR-34a did not change (data not 
shown). This suggests that only the former miRNA could 
have a role in regulating MYCN mRNA after LMNA 
knock-down. In fact, up-regulating MYCN in SH-SY5Y 
control cells, they acquired a stem-like phenotype; while 
down-regulating MYCN in LMNA-KD cells, we were 
able to restore a more mature phenotype. On the other 
hand, overexpression of the MYCN gene correlates with 
increased stemness characteristics [35–37]. In addition, 
the role of the MYCN gene in promoting tumor invasion, 
particularly in NB cells, is well known [38–40]. However, 
LMNA gene expression did not change when we increased 
MYCN in SH-SY5Y cells, indicating that an inverse 
correlation between LMNA and MYCN does not exist. 
Moreover, an in silico analysis of the LMNA promoter did 
not evidenced the presence of the Myc family transcription 
factors peculiar consensus sequence.
Our data provide new mechanistic insight into the 
development of a stem-like NB TIC population. In a tumor-
mass, TICs constitute a rare tumorigenic cell population 
responsible for sustaining tumor growth, metastases and 
relapse. Our data may provide opportunities to develop new 
personalized therapeutic strategies based on the molecular 
profile of the tumor.
MATERIALS AND METHODS
Human NB biopsy RNA extraction and  
real-time RT-PCR
Total RNA was extracted from twenty-three frozen 
biopsies of human newly diagnosed NBs obtained from 
Department of Pediatrics and Infantile Neuropsychiatry 
of Sapienza University, Rome using TRIzol reagent 
(Life Technologies) according to the manufacturer’s 
instructions. RNA was reverse-transcribed, and real-time 
PCR performed as described below. The amplification 
efficiencies of the primers for MYCN and LMNA genes 
were tested and resulted identical (LMNA efficiency = 2.1; 
MYCN efficiency = 2.0). Institutional written informed 
consent was obtained from the patient’s parents or legal 
guardians according to the local institutional guidelines.
Cell line maintenance and sphere formation
The SH-SY5Y NB cell line was purchased from 
ATCC. In this study, we also used two SH-SY5Y-derived 
clones, LMNA-KD and control (CTR) cells that were 
grown as previously described [5]. The LAN-5 NB 
cell line (a gift from Dr. Doriana Fruci) was grown in 
RPMI-1640 medium (Gibco) supplemented with 10% 
FBS (Hyclone), 2 mML-glutamine and 1% penicillin/
streptomycin in a fully humidified incubator containing 
5% CO2 at 37°C. To obtain spheres, cells were plated in 
a serum-free media in 60-mm, low-attachment culture 
dishes at a density of 9.5 × 105 cells/cm2 and cultured in 
Neurobasal Medium (Gibco) supplemented with 20 ng/ml 
Epidermal Growth Factor (EGF, Sigma), 40 ng/ml basic 
Fibroblast Growth Factor (bFGF, Sigma), 1% neuronal 
supplement N2 (Gibco) and B27 (Gibco), and 2 μg/ml 
heparin. Three days after seeding, the cells formed floating 
neurosphere-like structures that grew rapidly until day 7. 
Before these structures became necrotic, we harvested and 
suspended them in Accutase enzymatic solution (Gibco) 
for 5 min at 37°C and then mechanically dissociated into 
a single-cell suspension. The cells were re-seeded in the 
same conditions as above, and the secondary spheres 
were allowed to form. As positive and negative controls, 
we used NB LAN-5 and SH-SY5Y cell lines, respectively. 
The secondary spheres were measured using ImageJ 
software and the value of diameter expressed in μm. 
TICs were derived by harvesting the secondary spheres, 
treating them with Accutase enzymatic solution (Gibco) 
for 5 min at 37°C and then mechanically dissociating them 
into a single-cell suspension. These cells were seeded in 
adherent conditions in the presence of 1:1 mixture of 
Eagle’s Minimum Essential Medium and F12 medium 
(Gibco) supplemented with 10% FBS (Hyclone), 2 mM 
L-glutamine, 0.5% non-essential amino acids, 0.5% 
sodium pyruvate and 1% penicillin and streptomycin. 
mES cells were cultured following the protocol provided 
by ATCC (ES-D3, CRL-1934 ATCC).
Total RNA preparation
Total RNA was isolated using a Total RNA 
purification kit (Norgen Biotek). RNA quantity was 
determined by measuring absorbance at 260 nm using 
a NanoDrop UV-VIS spectrophotometer. The quality 
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and integrity of each sample was confirmed using a 
BioAnalyzer 2100 (Agilent RNA 6000 Nanokit); samples 
with an RNA Integrity Number (RIN) index lower than 
8.0 were discarded.
PCR array
RNA was reverse transcribed using TaqMan 
MicroRNA Reverse Transcription kit (Applied 
Biosystems). cDNA was preamplified using TaqMan 
PreAmp Master Mix (Applied Biosystems). qRT-PCR 
was performed with an Applied Biosystem 7900HT 
thermal cycler using TaqMan human microRNA array 
(TaqMan Human microRNA Array A #4398977 and 
B v3.0 #442812; Applied Biosystems) according to 
manufacturer’s instructions. The downstream analysis 
filtered out miRNAs not detected in both cell lines (293), 
whereas those specifically expressed either in LAN-
5 or in SH-SY5Y were considered and reported as cell 
line-specific. Data were then normalized calculating 
the ∆Ct value for single miRNA against the average 
of the specific controls for each card according to 
manufacturer’s instructions. Differential expression 
analysis was performed according to ∆∆Ct method and 
only RQ ≥ 2 fold-change were considered for further 
analysis. miRNAs clusters were generated through the 
DIANA web tool mirPath v2.0 using miRBase MIMAT 
IDs (Release 21) remapped to the newest human genome 
assembly (GRCh38) to avoid duplicate entries present in 
the previous release. Uniquely targets reported in TarBase 
database v7.0 were included in the clustering, predicted 
targets were not taken into account. False Discovery Rate 
(FDR) correction was applied to the original p-value and 
only clusters with corrected p-values < 0.05 were shown.
Real-time RT-PCR analysis
RNA was reverse-transcribed and real time PCR 
analysis were performed as previously described [41]. The 
specific primers used (each at a concentration of 200 nM) 
are reported in Supplementary Table 2. Each experiment 
was performed in triplicate. The expression data were 
normalized using the Ct values of GAPDH and TBP.
Side population
To analyze the side population phenotype, LMNA-
KD cells were stained according to the protocol of Goodell 
et al. [42]. Briefly, 5.0 × 106 cells/ml were suspended in 
pre-warmed DMEM. Hoechst 33342 (Sigma) was added at 
a final concentration of 5 μg/ml in the presence or absence 
of 50 μM verapamil (Sigma), and the cell samples were 
incubated for 90 min at 37°C with intermittent shaking. 
After incubation, the cells were washed with ice-cold PBS, 
resuspended in ice-cold PBS, and analyzed for Hoechst 
33342 efflux with a FACS Aria II (Becton Dickinson). 
The Hoechst 33342 dye was excited at 375 nm, which 
is near-ultraviolet, and the resultant fluorescence was 
measured at two wavelengths, using 450/40 BP and 
670 LP filters for the detection of Hoechst blue and 
red, respectively. All data were analyzed using the Diva 
6.1 Software (Becton Dickinson).
Tumor sphere CD133 immunofluorescence
Spheres were cultured as previously described, 
harvested and then allowed to spontaneously settle in a 
50-mL polypropylene conical tube. Excess supernatant 
was removed. Spheres were dispensed in an 8-well μ-Slide 
(Ibidi) and allowed to settle, and Matrigel from a 5X 
Matrigel BME Coating Solution (Trevigen) was added to 
0.1X. The cells were fixed in ice-cold methanol for 20 min 
and permeabilized in 0.5% Triton X-100 containing 
0.3% serum for 10 min. Blocking was carried out in 
Tris-buffered saline (TBS) solution with serum (1:5) for 
10 min. The primary antibody anti-CD133 (clone 293C3; 
Miltenyi Biotec) was diluted in the blocking solution with 
0.5% Tween-20, and the spheres were incubated overnight. 
The cells were washed three times in TBS and incubated 
with goat anti-mouse Alexa 594 F(ab)2 (in TBS plus 0.5% 
Tween-20). After three washes in TBS, the nuclei were 
stained with Hoechst 33342 Images were acquired using 
a confocal laser scanning microscope (Leica Confocal 
Microsystem TCS SP5). The images were processed using 
Leica Application Suite 6000, the brightness and contrast 
of the acquired images were adjusted, and the figures were 
generated using Adobe Photoshop 7.0.
Immunocytochemistry in murine ES
mES were fixed in 4% paraformaldehyde for 
10 minutes and incubated overnight at 4°C with the 
following primary antibodies used at 1:100: mouse 
monoclonal anti-Oct4 (OCT4; BD) and goat anti-Lamin 
A/C (JOL2; Chemicon Int.). After three washes with 
PBS, the cells were incubated with a 1:100 dilution 
of fluorescent-conjugated secondary antibodies for 
1 h at room temperature. Secondary antibodies were: 
donkey anti-mouse IgG Alexa-Fluor 555 (Jackson 
ImmunoResearch) and donkey anti-goat IgG Alexa-
Fluor 488 (Jackson ImmunoResearch). Negative controls 
were tested by incubation of only the secondary antibody 
without a primary antibody incubation: all secondary 
antibodies were negative for non-specific staining. 
After three washes, the sections were mounted with 
VECTASHIELD (Vector Laboratories) plus DAPI.
N-Myc FACS analysis
SH-SY5Y CTR, LMNA-KD cells and TICs 
were analyzed by indirect immunofluorescence. The 
cells were harvested, washed in cold 1X PBS and 
fixed (1 × 106 cells/ml) in a solution containing cold 
acetone/methanol (1:4 v/v) in 50% 1X PBS. For each 
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sample, 1 × 106 cells were incubated with the human 
monoclonal antibody anti-N-Myc (Santa Cruz) in 
medium containing 10% FBS and 0.5% Tween 20 for 
1 h at room temperature. After washing in PBS, the 
cells were incubated with FITC-conjugated goat anti-
mouse IgG (BD, Pharmingen) in PBS for 50 min. 
After an additional wash in PBS, the samples were 
measured using a FACSCalibur cytofluorimeter (Becton 
Dickinson). Samples incubated with IgG isotype control 
antibody were used as negative controls, and NB LAN-5 
cells were used as a positive control. The analysis was 
performed using the CellQuest software package. To 
determine the N-Myc immunofluorescence positivity 
we used the method of 2% of background.
Colony-forming assay
The LMNA-KD and sphere-derived adherent cell 
line were seeded at decreasing clonal densities (range: 
15–1,000 cells/dish) in 60-mm Petri dishes. Fifteen days 
after seeding, the cells were fixed for 10 min in ice-
cold methanol. A solution of 0.5% crystal violet in 25% 
methanol was added to the monolayer for 30 min. The 
dishes were then washed with ddH2O, and the colonies (at 
least 50 cells) were counted. The results were expressed as 
plating efficiency (percentage of colonies formed from the 
number cells seeded).
In vivo experiments
Six- to eight-week-old CD-1 male nude (nu/nu) 
mice weighing 22–24 g were purchased from Charles 
River Laboratories (Calco, Italy). The procedures 
involving mouse care were in compliance with the 
Regina Elena National Cancer Institute animal care 
guidelines and with international directives (directive 
2010/63/EU of the European parliament and council; 
Guide for the Care and Use of Laboratory Animals, 
United States National Research Council, 2011). 
To evaluate the tumorigenic ability of LMNA-
KD cells or sphere-derived adherent cells, the 
mice were injected subcutaneously into the left 
flank with various concentrations of cells (from 
5 × 104 to 1 × 107 cells/mouse) in 200 μl of Matrigel 
(BD Biosciences-Discovery Labware). Each group 
included five mice. Tumor sizes were measured three 
times a week in two dimensions using a caliper, and 
tumor weight was calculated using the following 
formula: a × b2/2, where a and b are the long and short 
diameters of the tumor, respectively.
Histopathological analysis
The engrafted tumors were fixed with 4% phosphate-
buffered formalin, and paraffin-embedded sections were 
stained using hematoxylin and eosin (H&E). The sections 
were then subjected to morphological analysis.
miRNA assays
Equal amounts of RNA were reverse transcribed with 
the TaqMan® MicroRNA Reverse Transcription Kit (Applied 
Biosystems) according to the manufacturer’s  instructions, 
with a custom 1X RT primer pool (hsa-miR-101–3p 
ID 002253; U6 snRNA ID 001973; hsa-miR-424 ID 000604; 
hsa-miR-34a ID 000426; hsa-miR-21 ID 000397; hsa-
miR-504 ID 002084; hsa-miR-92a ID 000431). Real time 
PCR analysis was performed with an Applied Biosystems 
7900HT thermal cycler using 20X Individual TaqMan® 
MicroRNA Assays.
Hsa-miR-101 inhibitor and mimic
SH-SY5Y control and LMNA-KD cells were 
seeded at a density of 5 × 104 cells/cm2. After 24 h, the 
cells were transfected overnight in the presence of 10% 
FBS with mirVana miRNA inhibitor, miRNA mimic 
or the respective negative controls. Lipofectamine 
RNAiMAX Reagent (Life Technologies) was used as 
the transfection reagent, according to the manufacturer’s 
instructions. We transfected the has-miR-101 inhibitor 
(MH11414, Ambion) and the mimic (MC11414, Ambion) 
at a final concentration of approximately 50 nM. The 
mirVana miRNA inhibitor and mimic negative control 
were used at the same final concentration of 50 nM. 
Samples were harvested at 72 h to perform mRNA 
expression analysis.
Statistical analysis
Student’s t test (unpaired, two-tailed) was used 
for statistical comparison of different tumor weights and 
between two groups. If there were more than two groups, 
we used the one-way ANOVA test.
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